While various published guidelines generally align on recommendations for first-line agents, recommendations for second- and third-line therapies vary. Treatments with support across guidelines include topical clindamycin, oral tetracyclines, combination clindamycin and rifampicin therapy, adalimumab, and wide local excision. Biologic therapy with adalimumab is recommended for patients with treatment-resistant, moderate to severe hidradenitis suppurativa.
Pain management should be offered as needed, and general measures to improve quality of life, such as smoking cessation, weight loss, and help with bandaging lesions, should be offered to all patients with hidradenitis suppurativa.
Two recent phase 3 studies evaluating the efficacy and safety of bimekizumab in adults with moderate to severe hidradenitis suppurativa met their primary and secondary endpoints, suggesting that targeting IL-17F in addition to IL-17A may be a promising therapeutic strategy in this population.
Learn more about treatment guidelines for chronic hidradenitis suppurativa.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: William D. James. Fast Five Quiz: Hidradenitis Suppurativa Management - Medscape - Jan 27, 2023.